Indian researchers are teaming up to fight major health issues like diabetes, blood cancer, fatty liver, and liver cell damage through innovative herbal drugs. Labs under the Council of Scientific and Industrial Research (CSIR), including the National Botanical Research Institute (NBRI), Central Institute of Medicinal and Aromatic Plants (CIMAP), Indian Institute of Toxicology Research (IITR), and Central Drug Research Institute (CDRI), have created 13 key herbal formulations targeting these chronic conditions.
This push highlights India’s booming herbal healthcare sector, where ancient Ayurvedic wisdom meets cutting-edge science to deliver affordable, effective natural remedies. Startups, scientists, and government leaders spotlighted this progress at the recent two-day CSIR Startup Conclave in New Delhi, showing how these lab creations can reach everyday people and global markets.
Standout among the drugs is BGR-34, a diabetes treatment developed by NBRI and CIMAP. It combines six powerful herbs—Daruharidra, Giloy, Vijaysar, Gudmar, Manjistha, and Methi—to help control blood sugar levels. Now, experts see it as a game-changer for reversing diabetes long-term, aligning with a worldwide shift toward curing the condition, not just managing it.
Other breakthroughs include Paclitaxel, extracted from the Arjuna tree bark to treat blood cancer, and Picroliv, which tackles fatty liver and liver degeneration. These herbal drugs blend traditional Indian medicine with modern validation, making them competitive on the world stage.
Union Science and Technology Minister Dr. Jitendra Singh visited the event and praised the “lab to people” innovation model. He encouraged startups to take these government-backed technologies and expand them globally, where demand for natural therapies is skyrocketing. Uttar Pradesh Chief Minister Yogi Adityanath joined him, urging faster commercialization of these herbal solutions to benefit more lives.
Dr. Sanchit Sharma, Executive Director of AIMIL Pharmaceuticals—the company marketing BGR-34—stressed the global trend. “The focus is moving from diabetes control to actual reversal,” he said. He added that products like BGR-34 show the perfect mix of Ayurveda and science, paving the way for a diabetes-free future.
The conclave also spotlighted India’s huge potential in the herbal medicine market. With consumers worldwide turning to natural options for lifestyle diseases, this sector is set for double-digit growth. Experts say validated Indian herbal drugs could help the country grab a bigger slice of this expanding pie.
Beyond drug development, CSIR labs like NBRI, CDRI, and CIMAP are breeding better medicinal plants to boost supply and quality, fueling the rise of India herbal medicine on the global scene.
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in world News on Latest NewsX. Follow us on social media Facebook, Twitter(X), Gettr and subscribe our Youtube Channel.
